Trials / Completed
CompletedNCT01969695
An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
An Extension Study of Venetoclax in Subjects With Advanced Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, open-label, multicenter, extension study. Subjects with non-Hodgkin's lymphoma (NHL) (excluding chronic lymphocytic lymphoma \[CLL\], small lymphocytic lymphoma \[SLL\], and mantle cell lymphoma \[MCL\]) who completed a prior ABT-199 study, or were active and assigned to ABT-199 when the study was completed, may roll over into this extension study. Subjects will receive ABT-199 during this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-199 | ABT-199 continuous once daily dosing |
Timeline
- Start date
- 2013-12-20
- Primary completion
- 2019-12-16
- Completion
- 2019-12-16
- First posted
- 2013-10-25
- Last updated
- 2019-12-19
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01969695. Inclusion in this directory is not an endorsement.